vs
Esperion Therapeutics, Inc.（ESPR）与null（SWIM）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是null的1.4倍（$168.4M vs $117.3M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 5.3%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs -14.4%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
该企业是一家源自美国的跨国律师事务所，1934年创立于加利福尼亚州洛杉矶，在诉讼业务、公司法务以及监管合规法律领域拥有深厚的行业积累与知名度，是全球颇具影响力的综合性律所之一。
ESPR vs SWIM — 直观对比
营收规模更大
ESPR
是对方的1.4倍
$117.3M
营收增速更快
ESPR
高出138.4%
5.3%
两年增速更快
ESPR
近两年复合增速
-14.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $117.3M |
| 净利润 | — | $-8.5M |
| 毛利率 | — | 31.7% |
| 营业利润率 | 50.6% | — |
| 净利率 | — | -7.3% |
| 营收同比 | 143.7% | 5.3% |
| 净利润同比 | — | -43.1% |
| 每股收益（稀释后） | $0.32 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRSWIM
| Q1 26 | — | $117.3M | ||
| Q4 25 | $168.4M | $100.0M | ||
| Q3 25 | $87.3M | $161.9M | ||
| Q2 25 | $82.4M | $172.6M | ||
| Q1 25 | $65.0M | $111.4M | ||
| Q4 24 | $69.1M | $87.3M | ||
| Q3 24 | $51.6M | $150.5M | ||
| Q2 24 | $73.8M | $160.1M |
净利润ESPRSWIM
| Q1 26 | — | $-8.5M | ||
| Q4 25 | — | $-7.0M | ||
| Q3 25 | $-31.3M | $8.1M | ||
| Q2 25 | $-12.7M | $16.0M | ||
| Q1 25 | $-40.5M | $-6.0M | ||
| Q4 24 | — | $-29.2M | ||
| Q3 24 | $-29.5M | $5.9M | ||
| Q2 24 | $-61.9M | $13.3M |
毛利率ESPRSWIM
| Q1 26 | — | 31.7% | ||
| Q4 25 | — | 28.0% | ||
| Q3 25 | — | 35.4% | ||
| Q2 25 | — | 37.1% | ||
| Q1 25 | — | 29.5% | ||
| Q4 24 | — | 24.6% | ||
| Q3 24 | — | 32.4% | ||
| Q2 24 | — | 33.1% |
营业利润率ESPRSWIM
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | -10.7% | ||
| Q3 25 | -11.4% | 13.3% | ||
| Q2 25 | 8.6% | 14.3% | ||
| Q1 25 | -34.0% | -4.4% | ||
| Q4 24 | -6.4% | -14.9% | ||
| Q3 24 | -31.0% | 8.9% | ||
| Q2 24 | 3.5% | 12.5% |
净利率ESPRSWIM
| Q1 26 | — | -7.3% | ||
| Q4 25 | — | -7.0% | ||
| Q3 25 | -35.9% | 5.0% | ||
| Q2 25 | -15.4% | 9.3% | ||
| Q1 25 | -62.2% | -5.4% | ||
| Q4 24 | — | -33.4% | ||
| Q3 24 | -57.2% | 3.9% | ||
| Q2 24 | -83.9% | 8.3% |
每股收益（稀释后）ESPRSWIM
| Q1 26 | — | $-0.07 | ||
| Q4 25 | $0.32 | $-0.06 | ||
| Q3 25 | $-0.16 | $0.07 | ||
| Q2 25 | $-0.06 | $0.13 | ||
| Q1 25 | $-0.21 | $-0.05 | ||
| Q4 24 | $-0.14 | $-0.24 | ||
| Q3 24 | $-0.15 | $0.05 | ||
| Q2 24 | $-0.33 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | — |
| 总债务越低越好 | — | $3.3M |
| 股东权益账面价值 | $-302.0M | $396.7M |
| 总资产 | $465.9M | $856.4M |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资ESPRSWIM
| Q1 26 | — | — | ||
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — |
总债务ESPRSWIM
| Q1 26 | — | $3.3M | ||
| Q4 25 | — | $279.8M | ||
| Q3 25 | — | $281.1M | ||
| Q2 25 | — | $281.5M | ||
| Q1 25 | — | $306.9M | ||
| Q4 24 | — | $281.5M | ||
| Q3 24 | — | $282.8M | ||
| Q2 24 | — | $282.4M |
股东权益ESPRSWIM
| Q1 26 | — | $396.7M | ||
| Q4 25 | $-302.0M | $405.9M | ||
| Q3 25 | $-451.4M | $408.4M | ||
| Q2 25 | $-433.5M | $398.4M | ||
| Q1 25 | $-426.2M | $381.1M | ||
| Q4 24 | $-388.7M | $387.2M | ||
| Q3 24 | $-370.2M | $416.6M | ||
| Q2 24 | $-344.2M | $408.1M |
总资产ESPRSWIM
| Q1 26 | — | $856.4M | ||
| Q4 25 | $465.9M | $823.2M | ||
| Q3 25 | $364.0M | $844.4M | ||
| Q2 25 | $347.1M | $822.1M | ||
| Q1 25 | $324.0M | $824.6M | ||
| Q4 24 | $343.8M | $794.2M | ||
| Q3 24 | $314.1M | $853.4M | ||
| Q2 24 | $352.3M | $830.0M |
负债/权益比ESPRSWIM
| Q1 26 | — | 0.01× | ||
| Q4 25 | — | 0.69× | ||
| Q3 25 | — | 0.69× | ||
| Q2 25 | — | 0.71× | ||
| Q1 25 | — | 0.81× | ||
| Q4 24 | — | 0.73× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.69× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $-47.7M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRSWIM
| Q1 26 | — | $-47.7M | ||
| Q4 25 | $45.2M | $23.3M | ||
| Q3 25 | $-4.3M | $51.0M | ||
| Q2 25 | $-31.4M | $36.0M | ||
| Q1 25 | $-22.6M | $-46.9M | ||
| Q4 24 | $-35.0M | $6.2M | ||
| Q3 24 | $-35.3M | $37.2M | ||
| Q2 24 | $-7.2M | $52.4M |
自由现金流ESPRSWIM
| Q1 26 | — | — | ||
| Q4 25 | — | $14.1M | ||
| Q3 25 | — | $45.2M | ||
| Q2 25 | — | $29.1M | ||
| Q1 25 | — | $-50.3M | ||
| Q4 24 | — | $-98.0K | ||
| Q3 24 | $-35.5M | $33.2M | ||
| Q2 24 | $-7.3M | $47.9M |
自由现金流率ESPRSWIM
| Q1 26 | — | — | ||
| Q4 25 | — | 14.1% | ||
| Q3 25 | — | 27.9% | ||
| Q2 25 | — | 16.8% | ||
| Q1 25 | — | -45.2% | ||
| Q4 24 | — | -0.1% | ||
| Q3 24 | -68.7% | 22.1% | ||
| Q2 24 | -9.9% | 29.9% |
资本支出强度ESPRSWIM
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 9.2% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 4.0% | ||
| Q1 25 | 0.0% | 3.1% | ||
| Q4 24 | 0.0% | 7.2% | ||
| Q3 24 | 0.3% | 2.7% | ||
| Q2 24 | 0.1% | 2.8% |
现金转化率ESPRSWIM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 6.29× | ||
| Q2 25 | — | 2.25× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 6.32× | ||
| Q2 24 | — | 3.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
SWIM
暂无分部数据
